Nykode Therapeutics CEO after another million-dollar deal: We have no competitors

Nykode Therapeutics – formerly Vaccibody – is not up for sale despite the fact that some of the world's biggest biotech businesses are fawning over its technology. CEO Michael Engsig says that they're open to partnerships, even though the company is economically sorted for the future.

Michael Engsig began his career in Norwegian Vaccibody as COO. Today, he has sealed another million.dollar deal as the company's CEO. | Photo: Vaccibody / PR

Some of the biggest biotech players in the world are swarming around the Norwegian company Nykode Therapeutics, which was named Vaccibody until yesterday.

The name change came alongside a fresh new deal with the US-based Regeneron, which could result in USD 875m going to Nykode Therapeutics's development and commercial efforts within cancer vaccines and infectious diseases.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs